Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 7/20 | 1.00 |
| ▸ | OSBP | P22059 | 6/20 | 1.00 |
| ▸ | RORC | P51449 | 5/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.84 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.84 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 0.84 |
| ▸ | USP2 | O75604 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.84 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.84 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.80 |
| ▸ | CRYAB | P02511 | 1/20 | 0.76 |
| ▸ | HMGCR | P04035 | 1/20 | 0.76 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.76 |
| ▸ | ITGAV | P06756 | 1/20 | 0.76 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.76 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.76 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.75 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.72 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1042866 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL6391967 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL159618 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL23960515 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL13076858 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL24937893 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL1176969 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL22095720 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL22559557 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A | |
| SCHEMBL288733 | 1.00 | NR1H3 (1.00) | NR1H3OSBPRORCGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4706644-A1 | RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES COMPRISING CHOLESTEROL | Mepsgen Co., Ltd. (KR) | 2026-03-11 | — | — | EP | claimed |
| WO-2025081338-A1 | MODULATION OF LOW DENSITY LIPOPROTEIN RECEPTOR FOR TREATMENT OF INFECTIONS | WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2025-04-24 | — | — | WO | claimed |
| CN-119112854-A | Application of agonist for targeting LXR alpha in liver macrophages | 中国人民解放军军事科学院军事医学研究院 | 2024-12-13 | — | — | CN | claimed |
| WO-2024228596-A1 | RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES COMPRISING CHOLESTEROL | (주) 멥스젠 | 2024-11-07 | — | — | WO | claimed |
| CN-118139894-A | Anti-PLA 2G2D constructs and uses thereof | 尖端免疫生医公司 | 2024-06-04 | — | — | CN | claimed |
| CN-117587045-B | Veratric cholesterol 22 (R) -hydroxylase VnCYP B27 gene and application thereof | 云南农业大学 | 2024-04-16 | — | — | CN | claimed |
| CN-117587045-A | Veratric cholesterol 22 (R) -hydroxylase VnCYP90B27 gene and application thereof | 云南农业大学 | 2024-02-23 | — | — | CN | claimed |
| CN-116322710-A | Pharmaceutical composition comprising gamma-cyclodextrin polymer and use thereof | 株式会社雷纳图斯 | 2023-06-23 | — | — | CN | claimed |
| US-20230043677-A1 | INHALABLE THERAPEUTICS | OREGON STATE UNIVERSITY (US) | 2023-02-09 | — | — | US | claimed |
| US-11536730-B2 | Methods for diagnosing motor neuron diseases | SWANSEA UNIVERSITY (GB) | 2022-12-27 | — | — | US | claimed |
| WO-2006007528-A2 | LXR/RXR-RELATED METHODS AND COMPOSITIONS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-01-19 | — | — | WO | claimed |
| WO-2004098506-A2 | TREATMENT FOR AGE-RELATED MACULAR DEGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1461028-A2 | TREATMENT FOR AGE-RELATED MACULAR DEGENERATION | The Regent of the University of California (US) | 2004-09-29 | — | — | EP | claimed |
| US-20030229062-A1 | Treatments for age-related macular degeneration (AMD) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-12-11 | — | — | US | claimed |
| US-20030162758-A1 | Treatment for age-related macular degeneration (AMD) | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2003-08-28 | — | — | US | claimed |
| CN-1434865-A | Regulation of the binding box transporter ABC1 | CV THERAPEUTICS INC (US) | 2003-08-06 | — | — | CN | claimed |
| WO-2003049685-A2 | TREATMENT FOR AGE-RELATED MACULAR DEGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-06-19 | — | — | WO | claimed |
| JP-2002506817-A | — | — | 2002-03-05 | — | — | JP | claimed |
| EP-1063989-A1 | PREVENTION AND TREATMENT OF ADHESIONS | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2001-01-03 | — | — | EP | claimed |
| WO-1999047136-A1 | PREVENTION AND TREATMENT OF ADHESIONS | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 1999-09-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043677-A1 | INHALABLE THERAPEUTICS | RNMT, CETP, NPC1L1 | NR1H3 25/4885OSBP 618/4885RORC 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.